BSX vs. GH: Boston Scientific vs. Guardant Health Stock Comparison

Company Profile

Boston Scientific (BSX) and Guardant Health (GH) both fall under the Health Care Equipment & Services industry group, but BSX is classified in Health Care Equipment & Supplies while GH is classified in Health Care Providers & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Guardant Health (GH) has an aggressive beta of 1.69, indicating higher sensitivity to broad-market moves, while Boston Scientific (BSX) is defensive at 0.57 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Boston Scientific (BSX) earns 14.12% on shareholders’ equity, ranked against its industry; Guardant Health (GH) has no ROE this period.

Guardant Health (GH) reports a negative net margin of -37.93%, usually indicating a net loss over the period. Meanwhile Boston Scientific (BSX) reports 16.62%, ranking against industry peers normally.

Guardant Health (GH) reports a negative operating margin of -37.06%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Boston Scientific (BSX) reports 19.05%, ranking against industry peers normally.

Profitability Metrics

Growth

Guardant Health (GH) at 32.88% sits in the top revenue growth quartile, while Boston Scientific (BSX) at 19.87% is closer to the peer norm — faster top-line expansion for GH.

Only one side can be read here: Boston Scientific (BSX) reports EPS growth of 55.20%, ranked against its industry; Guardant Health (GH) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Guardant Health (GH) at 3.60 keeps current ratio within its industry’s typical mid-range, while Boston Scientific (BSX) at 1.37 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BSX.

Only one side’s leverage can be read here: Boston Scientific (BSX) carries debt-to-equity ratio of 0.46 against its industry range, while Guardant Health (GH) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Boston Scientific (BSX) nor Guardant Health (GH) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Boston Scientific (BSX) nor Guardant Health (GH) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Boston Scientific (BSX) trades at 18.04 times trailing earnings, ranked against its peers, while Guardant Health (GH) has no P/E ratio this period.

Boston Scientific (BSX) at 2.94 prices around its industry’s typical P/S ratio, while Guardant Health (GH) at 15.96 clears its benchmark range — GH looks notably rich on sales.

Guardant Health (GH) reports a negative P/B ratio of -73.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Boston Scientific (BSX) reports 2.42, ranking against industry peers normally.

Valuation Metrics